Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
- PMID: 32282022
- DOI: 10.1001/jama.2020.6019
Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review
Abstract
Importance: The pandemic of coronavirus disease 2019 (COVID-19) caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) presents an unprecedented challenge to identify effective drugs for prevention and treatment. Given the rapid pace of scientific discovery and clinical data generated by the large number of people rapidly infected by SARS-CoV-2, clinicians need accurate evidence regarding effective medical treatments for this infection.
Observations: No proven effective therapies for this virus currently exist. The rapidly expanding knowledge regarding SARS-CoV-2 virology provides a significant number of potential drug targets. The most promising therapy is remdesivir. Remdesivir has potent in vitro activity against SARS-CoV-2, but it is not US Food and Drug Administration approved and currently is being tested in ongoing randomized trials. Oseltamivir has not been shown to have efficacy, and corticosteroids are currently not recommended. Current clinical evidence does not support stopping angiotensin-converting enzyme inhibitors or angiotensin receptor blockers in patients with COVID-19.
Conclusions and relevance: The COVID-19 pandemic represents the greatest global public health crisis of this generation and, potentially, since the pandemic influenza outbreak of 1918. The speed and volume of clinical trials launched to investigate potential therapies for COVID-19 highlight both the need and capability to produce high-quality evidence even in the middle of a pandemic. No therapies have been shown effective to date.
Comment in
-
Just a little bit more patience….Anaesth Crit Care Pain Med. 2020 Jun;39(3):383-384. doi: 10.1016/j.accpm.2020.05.004. Epub 2020 May 13. Anaesth Crit Care Pain Med. 2020. PMID: 32405519 Free PMC article. No abstract available.
-
Bronchoalveolar lavage findings in severe COVID-19 pneumonia.Intern Emerg Med. 2020 Oct;15(7):1333-1334. doi: 10.1007/s11739-020-02356-6. Epub 2020 May 15. Intern Emerg Med. 2020. PMID: 32415560 Free PMC article. No abstract available.
-
Why the Use of Angiotensin II May be a Fatal Mistake in COVID-19.Shock. 2020 Nov;54(5):697-699. doi: 10.1097/SHK.0000000000001577. Shock. 2020. PMID: 32453250 Free PMC article. No abstract available.
-
Clomipramine Could Be Useful in Preventing Neurological Complications of SARS-CoV-2 Infection.J Neuroimmune Pharmacol. 2020 Sep;15(3):347-348. doi: 10.1007/s11481-020-09939-2. Epub 2020 Jun 29. J Neuroimmune Pharmacol. 2020. PMID: 32601885 Free PMC article. No abstract available.
-
Potential role for nitazoxanide in treating SARS-CoV-2 infection.Am J Physiol Lung Cell Mol Physiol. 2020 Jul 1;319(1):L35-L36. doi: 10.1152/ajplung.00170.2020. Am J Physiol Lung Cell Mol Physiol. 2020. PMID: 33496642 Free PMC article. No abstract available.
Similar articles
-
Some drugs for COVID-19.Med Lett Drugs Ther. 2020 Apr 6;62(1595):49-50. Med Lett Drugs Ther. 2020. PMID: 32324177 No abstract available.
-
Treatment options for COVID-19: The reality and challenges.J Microbiol Immunol Infect. 2020 Jun;53(3):436-443. doi: 10.1016/j.jmii.2020.03.034. Epub 2020 Apr 4. J Microbiol Immunol Infect. 2020. PMID: 32307245 Free PMC article. Review.
-
An overview of the safety, clinical application and antiviral research of the COVID-19 therapeutics.J Infect Public Health. 2020 Oct;13(10):1405-1414. doi: 10.1016/j.jiph.2020.07.004. Epub 2020 Jul 13. J Infect Public Health. 2020. PMID: 32684351 Free PMC article.
-
Pharmacotherapy in COVID-19; A narrative review for emergency providers.Am J Emerg Med. 2020 Jul;38(7):1488-1493. doi: 10.1016/j.ajem.2020.04.035. Epub 2020 Apr 15. Am J Emerg Med. 2020. PMID: 32336586 Free PMC article. Review.
-
Psychopharmacology of COVID-19.Psychosomatics. 2020 Sep-Oct;61(5):411-427. doi: 10.1016/j.psym.2020.05.006. Epub 2020 May 18. Psychosomatics. 2020. PMID: 32425246 Free PMC article. Review.
Cited by
-
Immunogenicity and Determinants of Antibody Response to the BNT162b2 mRNA Vaccine: A Longitudinal Study in a Cohort of People Living with HIV.Vaccines (Basel). 2024 Oct 16;12(10):1172. doi: 10.3390/vaccines12101172. Vaccines (Basel). 2024. PMID: 39460338 Free PMC article.
-
Pro-Resolving Inflammatory Effects of a Marine Oil Enriched in Specialized Pro-Resolving Mediators (SPMs) Supplement and Its Implication in Patients with Post-COVID Syndrome (PCS).Biomedicines. 2024 Sep 29;12(10):2221. doi: 10.3390/biomedicines12102221. Biomedicines. 2024. PMID: 39457534 Free PMC article.
-
Identification of COVID-19-Associated Hepatitis in Children as an Emerging Complication in the Wake of SARS-CoV-2 Infections: Ambispective Observational Study.JMIRx Med. 2024 Oct 11;5:e48629. doi: 10.2196/48629. JMIRx Med. 2024. PMID: 39392692 Free PMC article.
-
Development and evaluation of an 18F-labeled nanobody to target SARS-CoV-2's spike protein.Front Nucl Med. 2022 Nov 23;2:1033697. doi: 10.3389/fnume.2022.1033697. eCollection 2022. Front Nucl Med. 2022. PMID: 39354971 Free PMC article.
-
Enhanced Treatment in Severe-Critical COVID-19 With Tocilizumab, Remdesivir, Dexamethasone: A Jordanian Cohort Study.Cureus. 2024 Aug 22;16(8):e67467. doi: 10.7759/cureus.67467. eCollection 2024 Aug. Cureus. 2024. PMID: 39314607 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous